At AstraZeneca, we aim to transform the treatment of respiratory disease with our growing portfolio of inhaled and biologics medicines, along with scientific research focused on three key areas: lung immunity, lung epithelium and lung regeneration. We are excited to join clinicians, researchers and scientists at the 2017 European Respiratory Society (ERS) International Congress to share the latest in respiratory science advancements.
Follow us on Twitter @AstraZeneca and join the conversation using #ERSCongress.
Investors and analysts can join the AstraZeneca ERS investor science event and webcast
In this Q&A, Roland Kolbeck, PhD provides a scientific perspective on emerging biologics and how following the science has opened the door for new discoveries - specifically highlighting the role of TSLP in asthma.
Looking into our labs
What are our respiratory scientists uncovering in our early science unit labs? Hear more about their research into the true disease drivers of asthma and COPD. These are the people pushing the boundaries of science so we can deliver the next generation of medicines focused on disease modification, early intervention and even the potential for cures.
Understanding drivers of inflammation in severe asthma
Eosinophils are the biological effector cells that are associated with inflammation and airway hyper-responsiveness in approximately 50% of asthma patients, leading to exacerbations, impaired lung function and asthma symptoms, making them a potentially important therapeutic target in severe asthma.
Severe asthma is a heterogenous disease with complex biology.
Inflammation can be characterised by a pattern of distinct signalling proteins (IL-4, IL-5, IL-13) and inflammatory cells (including eosinophils) in the lung.
Severe asthma is a heterogenous disease with complex biology and various immunological disease drivers, such as the signalling protein IL-13.
When IL-13 binds to receptors found on cells in the airways, it causes inflammation leading to exacerbations, making it an important therapeutic target in severe asthma.
Evolving clinical practice
Learn more about our products, pipeline, people, resources, news and commitment to following the science to improve patient outcomes.
Veeva ID: Z4-6921
Date of next review: September 2018